Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.
On The Dose podcast, Anita Ravi, M.D., and Keisha Walcott talk about designing health systems for women and girls who have experienced gender-based violence.
